| Code | CSB-RA023981MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to rocatinlimab, targeting TNFRSF4 (OX40, CD134), a member of the tumor necrosis factor receptor superfamily. TNFRSF4 functions as a costimulatory receptor expressed on activated T cells, playing a critical role in T cell activation, proliferation, and survival. The OX40-OX40L interaction regulates immune responses and has been implicated in various inflammatory and autoimmune conditions. Aberrant TNFRSF4 signaling contributes to the pathogenesis of atopic dermatitis, inflammatory bowel disease, and other immune-mediated disorders.
Rocatinlimab is a humanized IgG1 monoclonal antibody that binds to OX40, blocking its interaction with OX40 ligand and modulating pathogenic T cell responses. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF4-mediated immune regulation, studying T cell costimulation pathways, and exploring therapeutic mechanisms in inflammatory disease models. It supports studies examining immune checkpoint modulation and the role of OX40 in tissue inflammation and immune homeostasis.
There are currently no reviews for this product.